Plasma Levels of C1 Inhibitor Complexes and Cleaved C1 Inhibitor in Patients with Hereditary Angioneurotic Edema

Massimo Cugno, Jan Nuijens,* Erik Hack,* Anke Eerenberg,* Donatella Frangi, Angelo Agostoni, and Marco Cicardi Cattedra di Clinica Medica Università di Milano, Ospedale S. Paolo, 20142 Milano, Italy; and *Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands

Abstract

CI inhibitor (CI-Inh) catabolism in plasma of patients with hereditary angioneurotic edema (HANE) was assessed by measuring the complexes formed by $C\bar{1}$ -Inh with its target proteases (C1s, Factor XIIa, and kallikrein) and a modified (cleaved) inactive form of C1-Inh (iC1-Inh). This study was performed in plasma from 18 healthy subjects and 30 patients with HANE in remission: 20 with low antigen concentration (type I) and 10 (from 5 different kindreds) with dysfunctional protein (type II). Both type-I and type-II patients had increased $C\bar{1}-C\bar{1}$ -Inh complexes (P < 0.0001), which in type I inversely correlated with the levels of $C\bar{1}$ -Inh (P < 0.001). iC1-Inh was normal in all type-I patients and in type-II patients from three families with increased C1-Inh antigen, whereas $iC\overline{1}$ -Inh was higher than 20 times the normal values in patients from the remaining two families with C1-Inh antigen in the normal range. None of the subjects had an increase of either Factor XIIa-C1-Inh or kallikrein-C1-Inh complexes. This study shows that the hypercatabolism of C1-Inh in HANE patients at least in part occurs via the formation of complexes with $C\bar{1}$ and that genetically determined differences in catabolism of dysfunctional $C\overline{1}$ -Inh proteins are present in type-II patients. (J. Clin. Invest. 1990. 85:1215-1220.) complement • contact system • C1 inhibitor catabolism • C1 inhibitor deficiency \bullet dysfunctional C1 inhibitor

Introduction

Hereditary angioneurotic edema $(HANE)^{I}$ is due to the functional deficiency of the inhibitor of the first component of human complement (CĪ-Inh) (1). This protease inhibitor is involved in the regulation of several proteolytic systems in plasma including the complement system, the contact system of intrinsic coagulation and kinin release, and the fibrinolytic system (2). Two phenotypic variants of HANE are known: type I in which both functional and antigenic CĪ-Inh in

J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 0021-9738/90/04/1215/06 \$2.00 Volume 85, April 1990, 1215–1220

plasma is reduced and type II with functional deficiency but normal or markedly increased antigenic levels due to the presence of a dysmorphic protein (3, 4). Heterogeneity of the dysmorphic proteins has been demonstrated among different type-II HANE families (5). Studies of in vitro cell cultures have shown that monocytes from patients with HANE synthesize ~ 50% of normal C1-Inh compared with cells from normal subjects (6), which is in agreement with the autosomal dominant inheritance of the disorder (7). Independently from the severity of the disease (8), functional $C\bar{1}$ -Inh in plasma from patients with HANE ranges between 5 and 30% of the normal value instead of the expected 50%. In vivo turnover studies demonstrated that patients with HANE have an increased catabolism of normal $C\bar{1}$ -Inh along with its reduced synthesis (9). Lachmann and Rosen have suggested that the discrepancy between expected and actual functional C1-Inh levels in HANE is due to the catabolic behavior of $C\overline{1}$ -Inh: a level of 50% of normal cannot be maintained due to consumption of $C\bar{1}$ -Inh via the formation of complexes with its target proteases ($C\bar{l}r$, $C\bar{I}s$, Factor XIIa, and kallikrein) (10). Indirect proof that C1 is activated in both types of HANE during asymptomatic periods comes from the observation that plasma levels of the natural substrates of activated C1, i.e., C4 and C2, are reduced (11, 12). Zuraw and Curd (13) have found, in type I patients, an increase of a modified inactive form of C1-Inh of 94 kD. Since this 94-kD C1-Inh was generated in vitro by contact system activation but not by complement activation, they suggested that contact system activation may be an important mechanism in the pathophysiology of HANE as first proposed by Landerman (14). However, evidence that $C\bar{1}$ -Inh is indeed consumed by reacting with its target proteases in asymptomatic HANE patients is lacking, as well as is clear-cut proof that the contact system is hyperactivated (13, 15-19).

Despite the description of several highly sensitive assays for $C\overline{I}$ -Inh complexes in plasma (13, 20–24), only few data are as yet available concerning complex levels in plasma from HANE patients.

The present study reports on the quantification of $C\bar{l}$ -Inh complexes in plasma from asymptomatic HANE patients and supports the notion that levels of $C\bar{l}$ -Inh in these patients are lower than expected due to activation of C1. Moreover, quantification of modified (cleaved) inactive $C\bar{l}$ -Inh (i $C\bar{l}$ -Inh) revealed genetically determined differences in the catabolism of dysfunctional proteins in patients with type-II HANE.

Methods

Subjects and blood sampling

30 HANE patients, aged 14–66 yr, were studied. 16 were males and 14 were females. The patients (20 type I and 10 type II) were in remission (attack-free and without treatment for at least 3 mo). 18 healthy donors

Address reprint requests to Dr. M. Cicardi, Clinica Medica, Università di Milano, Ospedale S. Paolo, 20142 Milano, Italy.

Received for publication 20 June 1989 and in revised form 17 November 1989.

^{1.} Abbreviations used in this paper: $C\overline{I}$ -Inh, inhibitor of the first component of human complement; i $C\overline{I}$ -Inh, modified (cleaved) inactive $C\overline{I}$ -Inh; HANE, hereditary angioneurotic edema; RID, radial immunodiffusion.

(9 males and 9 females ranging in age between 25 and 62 yr) served as controls. Blood samples were obtained by clean venipuncture without stasis and collected in siliconized vacutainer tubes (Becton Dickinson, Plymouth, UK) to which EDTA (10 mM) and Polybrene (0.05%, wt/vol) had been added to prevent in vitro activation of the complement and the contact system (20, 24). Tubes were centrifuged at 1,300 g, at room temperature, for 10 min and plasma was aliquoted and stored in polystyrene tubes at -70° C until tests were performed.

Procedure

RIAs for CI-Inh species were performed as described in detail previously (20, 25-27).

 $C\overline{I}$ -Inh complexes. MAb KOK 12, which binds to both complexed $C\overline{I}$ -Inh and $iC\overline{I}$ -Inh, but not to native $C\overline{I}$ -Inh, was coupled to Sepharose beads and incubated with plasma samples. After washing the Sepharose with saline, bound complexes were detected by subsequent incubation with ¹²⁵I-labeled polyclonal antiprotease antibodies (¹²⁵I-anti-Factor XII, ¹²⁵I-antikallikrein, or ¹²⁵I-anti-C\overline{I}s). After another washing procedure, Sepharose-bound radioactivity was measured. As standards in the appropriate assay we used serial dilutions of plasma in which a maximal amount of Factor XIIa–CĪ-Inh (i.e., 0.375 μ M) and kallikrein–CĪ-Inh (i.e., 0.341 μ M) complexes was generated by incubation with dextran sulphate and serum in which a maximal amount of CĪ–CĪ-Inh (0.360 μ M) complexes was generated by incubation with heat-aggregated human IgG (20, 24, 27). Intra- and interassay coefficients of variation were < 10%. Details on this as well as on the preparation and stability of the standards are given elsewhere (20, 27).

 $C\bar{I}$ -Inh antigen and $iC\bar{I}$ -Inh. In the assay for $C\bar{I}$ -Inh antigen, a MAb (R II) that binds all forms of $C\bar{I}$ -Inh (native $C\bar{I}$ -Inh, complexed $C\bar{I}$ -Inh, and $iC\bar{I}$ -Inh) was used. $iC\bar{I}$ -Inh was measured with a MAb (K II), that binds to $iC\bar{I}$ -Inh, but not to native and complexed $C\bar{I}$ -Inh (25). Binding of $C\bar{I}$ -Inh species to these MAbs was detected using ¹²⁵I-labeled polyclonal anti- $C\bar{I}$ -Inh antibodies. Levels of antigenic $C\bar{I}$ -Inh and $iC\bar{I}$ -Inh were expressed in micromolar by reference to pooled normal plasma that contained 2.5 μ M of antigenic $C\bar{I}$ -Inh and 0.08 μ M of $iC\bar{I}$ -Inh.

Functional $C\bar{I}$ -Inh. This assay is based on the principle that only functional $C\bar{I}$ -Inh will bind to $C\bar{I}s$. Plasma samples were incubated with purified $C\bar{I}s$ coupled to Sepharose. Binding of $C\bar{I}$ -Inh to the $C\bar{I}s$ -Sepharose was detected by subsequent incubation with ¹²⁵I-labeled polyclonal anti– $C\bar{I}$ -Inh. Values for functional $C\bar{I}$ -Inh were expressed in micromolar using pooled normal plasma that contained 2.5 μ M of functional $C\bar{I}$ -Inh as standard.

Prekallikrein and Factor XII were measured by specific RIAs that have been described previously (20). Values were expressed in micromolar by comparison with pooled normal plasma that contained 0.57 μ M of prekallikrein and 0.50 μ M of Factor XII.

Chromogenic assay for functional $C\overline{I}$ -Inh was performed with the $C\overline{I}$ -Inh reagent kit of Immuno (Vienna, Austria). This method is based on the measurement of chromogenic groups released from pyrogluta-myl-glycyl-arginin-pNA (Kabi Ab, Stockholm) which is specifically split by $C\overline{I}$ s. Intra- and interassay coefficients of variation are < 10%.

Radial immunodiffusion (RID) for $C\bar{1}$ -Inh and C4 antigen was performed according to Mancini et al. (28) (NOR-Partigen; Behring, Marburg, FRG).

SDS-PAGE and immunoblotting analysis of $C\overline{I}$ -Inh. Total $C\overline{I}$ -Inh (with MAb RII) and i $C\overline{I}$ -Inh (with MAb KII) were immunoprecipitated from plasma by incubating 25 μ l of plasma for 5 h at room temperature with 80 μ g of MAb coupled to Sepharose. After a washing procedure, Sepharose-bound protein was eluted into nonreducing SDS sample buffer by incubation for 10 min at 100°C. The Sepharose beads were pelleted and the supernatants ("immunoprecipitates") were subjected to SDS-PAGE (7% wt/vol) slab. After electrophoretic transfer of proteins from the gel onto nitrocellulose sheets, C \overline{I} -Inh species on the blots were visualized by incubation with MAb RII purified by affinity chromatography on protein A–Sepharose and radiolabeled with ¹²⁵I by Iodogen method, followed by autoradiography. Details of the procedures were as described previously (29). The apparent molecular mass of proteins was estimated by comparison with the high-molecular weight protein markers of Bio-Rad Laboratories (Richmond, CA).

Statistics

The results were expressed as median and range; the Kruskal Wallis analysis of variance was performed and the significance of the differences between groups was assessed by the nonparametric test of Wilcoxon-Mann-Whitney. A *P*-value of < 0.05 was considered to indicate a statistically significant difference.

Results

Median values and ranges of the measurements in patients and healthy controls are presented in Table I. The results showed a significant correlation between RID and RIA for $C\bar{1}$ -Inh antigen (n = 48, r = 0.92, x/y = 0.96) and between chromogenic assay and RIA for functional $C\bar{1}$ -Inh (n = 48, r = 0.98, x/y = 0.99).

Patients with type-I HANE. Plasma levels of antigenic and functional CĪ-Inh and of C4 antigen were significantly (P < 0.0001) reduced as compared with those in healthy volunteers. Prekallikrein antigen was slightly decreased in patients compared with healthy controls, but the difference did not reach statistical significance. CĪ-CĪ-Inh complexes in plasma were significantly increased compared with the controls (P < 0.0001); levels of these complexes inversely correlated with functional (r = -0.78, P < 0.001; Fig. 1) and antigenic (r = 0.66, P < 0.001) CĪ-Inh. Plasma levels of Factor XIIa-CĪ-Inh, kallikrein-CĪ-Inh, and Factor XII in the patients were not different from those in healthy volunteers.

Patients with type-II HANE. As for type-I patients, $C\bar{1}-C\bar{1}$ -Inh complexes were significantly increased (P < 0.0001) compared with the controls, but neither correlated with functional C $\bar{1}$ -Inh nor with C $\bar{1}$ -Inh antigen. A significant increase in plasma levels of iC $\bar{1}$ -Inh was found (P < 0.005). When data were assembled for families (Table II), two groups could clearly be identified: group 1 (family a and b) with C $\bar{1}$ -Inh antigenic levels (determined by RID) that ranged between 51 and 67% of normal, and group 2 (family c, d, and e) with C $\bar{1}$ -Inh levels exceeding 100%. The two groups markedly differed in iC $\bar{1}$ -Inh levels which were normal in group 2 and higher than 20 times the normal value in group 1. Other measurements were similar in both groups. In group 1, levels of antigenic C $\bar{1}$ -Inh obtained with the RIA appeared slightly higher compared with those obtained by RID.

SDS-PAGE analysis of dysfunctional CI-Inh proteins. Immunoprecipitates of $C\bar{1}$ -Inh species from plasma of patients with type-II HANE were subjected to SDS-PAGE and immunoblot analysis (Fig. 2). Immunoblots of antigenic CI-Inh (RII-immunoprecipitate) from pooled normal plasma showed a major protein band of M_r 110,000, whereas those from plasma of all patients from group 1 revealed pronounced protein bands of M_r 110,000 and 98,000. Immunoblots of iC1-Inh (KII-immunoprecipitates) from pooled normal plasma revealed only a faint protein band of M_r 98,000. In contrast, pronounced bands of M_r 98,000 were observed on immunoblots of iC1-Inh from patients' plasma samples of group 1. Immunoblot analysis of antigenic C1-Inh from plasma of patients from family c and d (group 2) revealed a major protein band of M_r 110,000 together with a band of M_r 180,000, whereas no protein bands were observed on immunoblots of iCI-Inh from these plasma samples. The results of RIAs that

	Healthy subjects median (range) n = 18	Type-I HANE median (range) n = 20	Type-II HANE median (range) n = 10
Functional C ₁ -Inh (chromogenic) %	94	16*	15*
	(69–119)	(0-37)	(4-30)
C_1^- -Inh antigen (RIA) μM	2.19	0.49*	2.94**
	(1.30-3.45)	(0.08-0.73)	(2.35-6.55)
iC_1^- -Inh (RIA) μM	0.08	0.09	1.04**
	(0.06-0.13)	(0.03-0.13)	(0.05-3.77)
C4 antigen (RID) %	99	19*	21*
	(67–130)	(0-67)	(9–55)
$C_1^ C_1^-$ -Inh (RIA) μM	0.007	0.013*	0.017*
	(0.001-0.011)	(0.003-0.028)	(0.008-0.028)
Kallikrein– C_1 -Inh (RIA) μM	0.0002	< 0.0002	< 0.0002
	(<0.0002-0.0005)	(<0.0002)	(<0.0002-0.0004)
Factor XIIa– C_1 -Inh (RIA) μM	<0.0002	< 0.0002	< 0.0002
Prekallikrein (RIA) μM	0.50	0.43	0.49
	(0.35-0.627)	(0.31-0.62)	(0.34–0.62)
Factor XII (RIA) µM	0.49	0.48	0.49
	(0.18-0.81)	(0.21 - 0.70)	(0.36-0.68)

Table I. Complement and Contact System Parameters in Healthy Subjects and HANE Patients in Basal Condition

% = percentage of normal human pooled plasma. Statistical significance vs. normals: *P < 0.0001, **P < 0.005.

specifically detect dimers of albumin and $C\bar{1}$ -Inh indicated that plasma of patients from family c and d contained high levels of these dimers (unpublished observation). The protein band of M_r 180,000 observed on the blots is compatible herewith.

Discussion

In this study we demonstrated elevated plasma levels of $C\bar{1}$ - $C\bar{1}$ -Inh complexes in asymptomatic patients with an inherited deficiency of $C\bar{1}$ -Inh. In patients with type-I HANE the levels of these complexes significantly correlated with anti-




Figure 1. Correlation between plasma levels of functional $C\overline{1}$ -Inh, determined by chromogenic assay, and $C\overline{1}$ - $C\overline{1}$ -Inh complexes in 20 type-I HANE patients.

genic and functional C1-Inh (P < 0.001). These observations suggest that C1 activation is at least in part responsible for the increased catabolism of C1-Inh found in asymptomatic patients with HANE (9), as proposed by Curd et al. (30), and thus for the apparent discrepancy between expected and actual levels of functional C1-Inh in this heterozygous disorder (10). A previous study, using an SDS-PAGE and immunoblotting technique, reported increased levels of $C\bar{1}$ - $C\bar{1}$ -Inh complexes in type-I HANE patients, but no statistical correlation with C1-Inh levels was performed (13). Our double antibody assay allows a direct quantification of these complexes and provides specificity by the use of a MAb that binds complexed $C\bar{1}$ -Inh. In vitro generation of complexes is avoided by drawing blood samples into EDTA and polybrene, a procedure that prevents activation of the contact system and the complement system via the classical pathway (20, 24, 27, 31).

To our knowledge, no data on the clearance of $C\bar{1}$ -Inh complexes in humans have been published. Recently, we estimated an apparent $t_{1/2}$ time of clearance of ~ 50 min, for both Factor XIIa-C1-Inh and kallikrein-C1-Inh complexes, from sequential measurements of these complexes in patients with sepsis (20) and we assume that $C\overline{1}-C\overline{1}$ -Inh complexes also have a similar $t_{1/2}$. Inasmuch as the actual $t_{1/2}$ may be much shorter and may vary among different patients' groups, the contribution of C1 activation to the catabolism of C1-Inh in HANE patients is difficult to assess. Quastel et al. have shown that the catabolism of CI-Inh in HANE is increased by $\sim 1\%$ of the plasma pool per hour compared with healthy individuals: the fractional catabolic rate was 3.5% of plasma pool per hour in HANE patients, vs. 2.5% in healthy controls (9). Based on the median levels of $C\overline{1}$ - $C\overline{1}$ -Inh and of $C\overline{1}$ -Inh antigen as measured by RIA (Tables I and II), and considering that the actual composition of $C\overline{1}$ - $C\overline{1}$ -Inh is $C\overline{1}rC\overline{1}s(C\overline{1}-Inh)_2$, the relative amount of C1-Inh complexed to C1 was 0.6% in healthy subjects and 5.3% in type-I HANE patients. These data suggest

Name	Family	Functional C ₁ -Inh (chromogenic)	C ₁ -Inh antigen (RID)	Cī-Inh antigen (RIA)	iCī-Inh (RIA)	Cī-Cī-Inh (RIA)
		%	%	%	μΜ	μM
Group 1						
A.C.	a	16	51	96	2.23	0.014
M.C.	а	17	67	108	3.77	0.025
P.M.	b	14	56	94	1.89	0.012
I.C.	b	27	63	121	3.01	0.028
L.C.	b	13	52	99	2.25	0.026
median		16	56*	99**	2.25*	0.025
(range)		(13–27)	(51–67)	(94–121)	(1.89–3.77)	(0.012-0.028)
Group 2						
P.P.	с	30	314	262	0.05	0.011
D.C.	d	14	242	226	0.19	0.020
S.T.	d	4	242	125	0.10	0.008
R.B.	e	6	117	114	0.09	0.020
M.R.B.	e	26	194	160	0.07	0.012
median		14	242	160	0.09	0.012
(range)		(4–30)	(117-314)	(114-262)	(0.05-0.19)	(0.008-0.020)

Table II. Complement Parameters in Type II HANE Patients

Group 1 (family a and b) includes patients with elevated concentrations of iC_1 -Inh and with C_1 -Inh antigen, measured by RID, below 100%. Group 2 (family c, d, and e) includes patients with normal concentrations of iC_1 -Inh and with C_1 -Inh antigen, measured by RID, above 100% of normal pooled plasma. Patients are designated with their name initials. Percentage values are obtained referring to a curve of serial dilutions of plasma pooled from 30 healthy individuals. Micromolar values are obtained as described in Methods. Median value for C_1 -Inh antigen with RID in normals is 98% (range 63–137%), median values for other parameters are reported in Table I. Statistical significance vs. group 2: *P = 0.0079; **P = 0.0159.

that the increase in $C\overline{1}$ -Inh catabolism in type-I HANE is at least in part due to complex formation with $C\overline{1}$.

In this study, we did not find an increase of Factor XIIa– $C\overline{1}$ -Inh or kallikrein– $C\overline{1}$ -Inh complexes despite the high sensitivity of the assays that can detect 0.05% activation of plasma Factor XII and prekallikrein (20). These results suggest that the extent of contact activation in HANE patients in basal condition is not enough to overcome the clearance of com-

plexes from the circulation. A new approach, such as with recently developed methods (19), may prove useful in defining the role of contact activation envisaged in HANE patients outside acute swellings (13, 14).

Patients with type-II HANE could be divided into two groups based on plasma levels of $C\bar{1}$ -Inh antigen and $iC\bar{1}$ -Inh. In group 1, antigenic $C\bar{1}$ -Inh, as measured by RID, ranges between 51 and 67% of normal and the concentration of $iC\bar{1}$ -




Figure 2. Immunoblotting of CI-Inh in pooled normal plasma and in patients with type-II HANE, group 1 (*right*) and group 2 (*left*), identified by their initials. Total CI-Inh antigen and iCI-Inh were immunoprecipitated from plasma by Sepharose-coupled MAb to total CI-Inh (RII) and to iCI-Inh (KII), respectively, and separated on nonreduced 7% SDS-PAGE. After electrotransfer to nitrocellulose and immunoblotting by ¹²⁵I-labeled MAb RII, bands were visualized by autoradiography.

Inh is at least 20 times higher than in pooled normal plasma (2,360-4,718%). The measurement of C1-Inh antigen by RIA in this group resulted in significantly higher levels than those found by RID. This difference may be ascribed to the presence of high levels of iC1-Inh, which is recognized by the monoclonal antibody used in the RIA, but poorly detected by the polyclonal antibody used in RID, as demonstrated by immunoblotting experiments (data not shown). In group 2, CI-Inh antigen exceeded 100% (117-314%) and iC1-Inh is normal or only slightly increased (66-238%). The immunoblotting experiments revealed that C1-Inh in group 1 was, for the major part, degraded into a form with M_r 98,000, whereas no such bands were observed on blots of C1-Inh from plasma of patients from group 2. We think that these differences reflect two different molecular mechanisms that may underlie type-II HANE. In group 1 (relatively low antigenic C1-Inh and high $iC\bar{1}$ -Inh levels) the mutation in the $C\bar{1}$ -Inh gene probably yields a CI-Inh protein which still can form complexes with target proteases such as C1s, but these complexes are not stable and are rapidly hydrolyzed into an active protease and iCI-Inh. The mutations that underlie this form of HANE thus render C1-Inh a true substrate for target proteases. Studies performed with dysfunctional molecules purified from patients with type-II HANE, suggest that some of the dysfunctional molecules indeed behave like substrates for target proteases (5, 32). For example, four of the eight dysfunctional $C\bar{1}$ -Inh molecules studied by Donaldson et al. (32) were cleaved by kallikrein, and did not form stable complexes with this target protease. We have recently prepared a recombinant CI-Inh protein with an arginine at position P3. This mutant protein does not form stable complexes with kallikrein, but instead is rapidly degraded by this protease (Eldering, E., C. C. M. Huijbregts, J. H. Nuijens, and C. E. Hack, manuscript in preparation). In group 2, the mutant $C\bar{1}$ -Inh protein probably does not interact with target proteases at all and accounts for higher levels of $C\overline{1}$ -Inh antigen due to a slower catabolism. The type-II group-2 patients in whom we detected high plasma levels of dimers between albumin and $C\overline{1}$ -Inh are very likely to have a substitution of P1 arginine by cysteine (33). The differences in type-II Hane patients of groups 1 and 2, as well as the variability in C1-Inh catabolism revealed by in vivo turnover studies (9), may thus reflect different mutations at the reactive center P1 (33-35) or other functionally important residues. In type-II patients, $C\bar{1}-C\bar{1}$ -Inh complexes did not significantly correlate with the levels of $C\overline{1}$ -Inh function. These complexes were higher in group 1 than in group 2 (Table II), although this difference was not statistically significant probably because of the small number of cases. It is possible that part of the complexes measured in group-1 patients is represented by the unstable complexes formed by the dysfunctional protein as proposed above.

Zuraw and Curd (13) studied nine type-I and 2 type-II HANE patients, using a monoclonal antibody that recognizes both native and cleaved $C\bar{I}$ -Inh. In that study, the ratio between inactive and total $C\bar{I}$ -Inh was increased in type-I patients and was normal in type II. Our present data cannot be directly compared because we used a different method (RIA vs. immunoblotting) and a different monoclonal antibody that does not react with the native $C\bar{I}$ -Inh (25). However, our results in type-I patients, as well as those from Zuraw and Curd, demonstrate that relative amount of modified inactive $C\bar{I}$ -Inh is increased compared with normal when referred to total content of $C\bar{l}$ -Inh, which is markedly reduced in these patients. Therefore, the increase in i $C\bar{l}$ -Inh, which results from the interaction of $C\bar{l}$ -Inh with as yet unknown proteases (25), is consistent with the hypercatabolism of $C\bar{l}$ -Inh, but cannot discriminate the catabolic pathway. For type II, it appears that both patients studied by Zuraw and Curd (13) belong to those that we called group 2 and we agree with their suggestion that the amount of catabolic product is dependent on the ability of the mutant $C\bar{l}$ -Inh to interact with proteases.

Acknowledgments

We are deeply indebted to Dr. Virginia H. Donaldson whose helpful suggestions prompted the authors to start this study.

This work is supported by grants from Consiglio Nazionale delle Ricerche Roma, and Special Project Basi Molecolari delle Malattie Ereditarie.

References

1. Donaldson, V. H., and R. R. Evans. 1963. A biochemical abnormality in hereditary angioneurotic edema. *Am. J. Med.* 35:37-44.

2. Davis, A. E., III. 1988. C1 Inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 6:595-628.

3. Rosen, F. S., C. A. Alper, J. Pensky, M. R. Klemperer, and V. H. Donaldson. 1971. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. *J. Clin. Invest.* 50:2143–2149.

4. Gadek, J. E., S. W. Hosea, J. A. Gelfand, and M. M. Frank. 1979. Response of variant hereditary angioedema phenotypes to danazol therapy. J. Clin. Invest. 64:280–286.

5. Donaldson, V. H., R. A. Harrison, F. S. Rosen, D. H. Bing, G. Kindness, J. Canar, C. J. Wagner, and S. Awad. 1985. Variability in purified dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema. *J. Clin. Invest.* 75:124–132.

6. Cicardi, M., T. Igarashi, F. S. Rosen, and A. E. Davis III. 1987. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J. Clin. Invest. 79:698-702.

7. Crowder, J. R., and T. R. Crowder. 1917. Five generations of angioneurotic edema. Arch. Intern. Med. 20:840-852.

8. Frank, M. M., J. A. Gelfand, and J. P. Atkinson. 1976. Hereditary angioedema: the clinical syndrome and its management. *Ann. Intern. Med.* 84:580-593.

9. Quastel, M., R. Harrison, M. Cicardi, C. A. Alper, and F. S. Rosen. 1983. Behavior in vivo of normal and dysfunctional $C\overline{I}$ inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest. 71:1041–1046.

10. Lachmann, P. J., and F. S. Rosen. 1984. The catabolism of C1 inhibitor and pathogenesis of hereditary angio-edema. *Acta Pathol. Microbiol. Immunol. Scand. Sect. C.* 92 (Suppl. 284):35-39.

11. Donaldson, V. H., and F. S. Rosen. 1964. Action of complement in hereditary angioneurotic edema: the role of C'1-esterase. J. Clin. Invest. 43:2204-2213.

12. Austen, K. F., and A. L. Sheffer. 1965. Detection of hereditary angioneurotic edema by demonstration of a reduction in the second component of human complement. *N. Engl. J. Med.* 272:649-656.

13. Zuraw, B. L., and J. G. Curd. 1986. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J. Clin. Invest. 78:567-575.

14. Landerman, N. S., M. E. Webster, E. L. Becker, and H. E. Ratcliffe. 1962. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy. 33:330-341.

15. Curd, J. G., L. J. Prograis, Jr., and C. G. Cochrane. 1980. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. *J. Exp. Med.* 152:742–747.

16. Cullmann, W., P. M. Koevary, N. Mueller, and W. Dick. 1982.

Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). *Clin. Exp. Immunol.* 49:618-622.

17. Schapira, M., L. D. Silver, C. F. Scott, A. H. Schmaier, L. J. Prograis, Jr., J. G. Curd, and R. W. Colman. 1983. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. *N. Engl. J. Med.* 308:1050–1053.

18. Cugno, M., L. Bergamaschini, L. Uziel, M. Cicardi, A. Agostoni, A. F. H. Jie, and C. Kluft. 1988. Haemostasis contact system and fibrinolysis in hereditary angioedema (C1-inhibitor deficiency). J. Clin. Chem. Clin. Biochem. 26:423-427.

19. Lämmle, B., B. L. Zuraw, M. J. Heeb, H. P. Schwarz, M. Berrettini, J. G. Curd, and J. H. Griffin. 1988. Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI. *Thromb. Haemostasis.* 59:151-161.

20. Nuijens, J. H., C. M. Huijbregts, A. J. M. Eerenberg-Belmer, J. J. Abbink, R. J. M. Strack van Schijndel, R. J. F. Felt-Bersma, L. G. Thijs, and C. E. Hack. 1988. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. *Blood.* 72:1841-1848.

21. Laurell, A.-B., U. Martensson, and A. G. Sjoeholm. 1979. Quantitation of C1r-C1s-C1 inactivator complexes by electroimmunoassay. *Acta Pathol. Microbiol. Scand. Sect. C Immunol.* 87:79-81.

22. Lewin, M. F., A. P. Kaplan, and P. C. Harpel. 1983. Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. Quantification by an enzyme-linked differential antibody immunosorbent assay. J. Biol. Chem. 258:6415–6421.

23. Kaplan, A. P., B. Gruber, and P. C. Harpel. 1985. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzymelinked differential antibody immunosorbent assay. *Blood*. 66:636–641.

24. Hack C. E., A. J. Hannema, A. J. M. Eerenberg-Belmer, T. A. Out, and R. C. Aalberse. 1981. A C1-inhibitor complex assay (INCA): a method to detect C1 activation in vitro and in vivo. *J. Immunol.* 127:1450-1453.

25. Nuijens, J. H., C. C. M. Huijbregts, G. M. van Mierlo, and C. E. Hack. 1987. Inactivation of C1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C1 inhibitor. *Immunology*. 61:387–389.

26. Eldering, E., J. H. Nuijens, and C. E. Hack. 1988. Expression of functional human C1-inhibitor in Cos cells. J. Biol. Chem. 263:11776-11779.

27. Nuijens, J. H., A. J. M. Eerenberg-Belmer, C. C. M. Huijbregts, W. O. Schreuder, R. J. F. Felt-Bersma, J. J. Abbink, L. G. Thijs, and C. E. Hack. 1989. Proteolytic inactivation of plasma $C\overline{l}$ inhibitor in sepsis. J. Clin. Invest. 84:443–450.

28. Mancini, G., A. Carbonara, and J. F. Heremans. 1965. Immunochemical quantitation of antigens by immunodiffusion. *Immunochemistry*. 2:235-240.

29. Hoekzema, R., A. J. Hannema, A. J. G. Swaak, J. Paardekooper, and C. E. Hack. 1985. Low molecular weight C1q in systemic lupus erythematosus. J. Immunol. 135:265-271.

30. Curd, J. G., M. Yelvington, R. J. Ziccardi, D. A. Mathison, and J. H. Griffin. 1981. Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema. *Clin. Exp. Immunol.* 45:261–270.

31. Nuijens, J. H., C. C. M. Huijbregts, M. Cohen, G. O. Navis, A. de Vries, A. J. M. Eerenberg, J. C. Bakker, and C. E. Hack. 1987. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C1-inhibitor and kallikrein-C1-inhibitor complexes by specific radioimmunoas-says. *Thromb. Haemostasis.* 58:778-785.

32. Donaldson, V. H., C. J. Wagner, B. Tsuei, G. Kindness, D. H. Bing, R. A. Harrison, and F. S. Rosen. 1987. Interactions of plasma kallikrein and C1s with normal and dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema. Analytic gel studies. *Blood.* 69:1096–1101.

33. Skriver, K., E. Radziejewska, J. A. Sieberman, V. H. Donaldson, and S. C. Bock. 1989. CpG mutations in the reactive site of human C1 inhibitor. J. Biol. Chem. 264:3066-3071.

34. Aulak, K. S., P. J. Lachmann, F. S. Rosen, and R. A. Harrison. 1988. Are the permitted P1 residue mutations in dysfunctional C1.ⁱnhibitor proteins more limited than predicted by point mutations of the 444 arg codon? *Complement.* 5:181–182. (Abstr.)

35. Aulak, K. S., P. A. Pemberton, F. S. Rosen, R. W. Carrell, P. J. Lachmann, and R. A. Harrison. 1988. Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 "reactive centre" (Arg⁴⁴⁴ His) mutation. *Biochem. J.* 253:615–618.